Research ArticleCancer

Structure-based design of small-molecule inhibitors of EBNA1 DNA binding blocks Epstein-Barr virus latent infection and tumor growth

See allHide authors and affiliations

Science Translational Medicine  06 Mar 2019:
Vol. 11, Issue 482, eaau5612
DOI: 10.1126/scitranslmed.aau5612

No holds Barr-ed for cancer treatment

Persistent latent infection with Epstein-Barr virus contributes to tumorigenesis in a variety of cancer types. The only viral protein that is consistently expressed in these tumors is Epstein-Barr nuclear antigen 1, which performs a variety of biological functions. To target this antigen, Messick et al. designed a series of chemical inhibitors and then tested them in vitro and in multiple mouse models of Epstein-Barr virus–associated cancer. The authors characterized the inhibitors using a variety of assays, examined the mechanism by which they work, and demonstrated preclinical effectiveness and suitable pharmacological properties, paving the way for further therapeutic development.

View Full Text

Stay Connected to Science Translational Medicine